Literature DB >> 11160182

The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1.

Y Le1, H Yazawa, W Gong, Z Yu, V J Ferrans, P M Murphy, J M Wang.   

Abstract

Prion diseases are transmissible and fatal neurodegenerative disorders which involve infiltration and activation of mononuclear phagocytes at the brain lesions. A 20-aa acid fragment of the human cellular prion protein, PrP(106-126), was reported to mimic the biological activity of the pathologic isoform of prion and activates mononuclear phagocytes. The cell surface receptor(s) mediating the activity of PrP(106-126) is unknown. In this study, we show that PrP(106-126) is chemotactic for human monocytes through the use of a G protein-coupled receptor formyl peptide receptor-like 1 (FPRL1), which has been reported to interact with a diverse array of exogenous or endogenous ligands. Upon stimulation by PrP(106-126), FPRL1 underwent a rapid internalization and, furthermore, PrP(106-126) enhanced monocyte production of proinflammatory cytokines, which was inhibited by pertussis toxin. Thus, FPRL1 may act as a "pattern recognition" receptor that interacts with multiple pathologic agents and may be involved in the proinflammatory process of prion diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160182     DOI: 10.4049/jimmunol.166.3.1448

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Pharmacophore model for bile acids recognition by the FPR receptor.

Authors:  Cristina Ferrari; Antonio Macchiarulo; Gabriele Costantino; Roberto Pellicciari
Journal:  J Comput Aided Mol Des       Date:  2006-09-14       Impact factor: 3.686

2.  Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.

Authors:  Clemencia Pinilla; Bruce S Edwards; Jon R Appel; Tina Yates-Gibbins; Marc A Giulianotti; Jose L Medina-Franco; Susan M Young; Radleigh G Santos; Larry A Sklar; Richard A Houghten
Journal:  Mol Pharmacol       Date:  2013-06-20       Impact factor: 4.436

Review 3.  Expression and signaling of formyl-peptide receptors in the brain.

Authors:  Fabio Cattaneo; Germano Guerra; Rosario Ammendola
Journal:  Neurochem Res       Date:  2010-11-02       Impact factor: 3.996

4.  Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.

Authors:  Susan M Young; Cristian M Bologa; Dan Fara; Bj K Bryant; Juan Jacob Strouse; Jeffrey B Arterburn; Richard D Ye; Tudor I Oprea; Eric R Prossnitz; Larry A Sklar; Bruce S Edwards
Journal:  Cytometry A       Date:  2009-03       Impact factor: 4.355

Review 5.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

6.  A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis.

Authors:  J Bylund; T Christophe; T Cristophe; F Boulay; A Romero; K Hellstrand; C Dahlgren
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 7.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

8.  Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.

Authors:  Eoin P Brennan; Karen A Nolan; Emma Börgeson; Oisín S Gough; Caitríona M McEvoy; Neil G Docherty; Debra F Higgins; Madeline Murphy; Denise M Sadlier; Syed Tasadaque Ali-Shah; Patrick J Guiry; David A Savage; Alexander P Maxwell; Finian Martin; Catherine Godson
Journal:  J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 10.121

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cells.

Authors:  Michael Gurevich; Tamir Tuller; Udi Rubinstein; Rotem Or-Bach; Anat Achiron
Journal:  BMC Med Genomics       Date:  2009-07-22       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.